Circulating miRNA biomarkers for sporadic Amyotrophic Lateral Sclerosis: a systematic meta-analysis and empirical validation

Narges Daneshafrooz  
Iran University of Medical Sciences

Mahammad Taghi Joghataei  
Iran University of Medical Sciences

Mehdi Mehdizadeh  
Iran University of Medical Sciences

Afagh Alavi  
University of Social Welfare and Rehabilitation Science

Mahmood Barati  
Iran University of Medical Sciences

Shahram Teimourian  
Iran University of Medical Sciences

Babak Zamani (✉ zamaniba3@gmail.com)  
Iran University of Medical Sciences  https://orcid.org/0000-0002-4527-5134

Research Article

**Keywords:** Amyotrophic lateral sclerosis, Biomarker, let-7f-5p, miR-338-3p

**DOI:** https://doi.org/10.21203/rs.3.rs-166195/v1

**License:** ☩  This work is licensed under a Creative Commons Attribution 4.0 International License.  
[Read Full License]
Abstract

Amyotrophic lateral sclerosis (ALS) is a lethal neurodegenerative disease that occurs as sporadic (sALS) in most cases. The disease is not curable, and its pathogenesis is not understood as yet. Given the intricacy of underlying molecular interactions and heterogeneity of ALS, the discovery of molecules contributing to disease onset and progression will open the way for advancement in prevention and therapeutic intervention. Here we conducted a meta-analysis of 12 circulating miRNA profiling studies using the robust rank aggregation (RRA) method, followed by enrichment analysis. We identified miR-451a and let-7f-5p as meta-signature miRNAs whose targets are involved in critical pathogenic pathways underlying ALS, including FoxO, MAPK, and apoptosis. A systematic review of 7 gene profiling studies elucidated that 241 genes upregulated in sALS circulation with concomitant being targets of the meta-signature miRNAs. Protein-protein interaction network analysis for selected targets revealed the main subcluster is involved in multiple cascades, which eventually leads to apoptosis. Besides, evaluation of relative expression of miRNAs by TaqMan RT-qPCR verified let-7f-5p is significantly downregulated in the plasma of patients. Furthermore, we verified the relative expression of two top-ranked upregulated miRNAs and found miR-338-3p significantly upregulated in ALS patients. Receiver operating characteristic (ROC) analysis indicated that let-7f-5p and miR-338-3p are useful plasma biomarkers for diagnosis and a potential therapeutic target for ALS disease.

Introduction

Amyotrophic Lateral Sclerosis (ALS) is an adult-onset, fatal neurodegenerative disease characterized by selective and progressive loss of upper and lower motor neurons in the cerebral cortex, brainstem, and spinal cord [1]. Death ultimately occurs due to respiratory failure 2-5 years following the onset of symptoms, though a small portion of patients survives longer [2]. The heterogeneity in the phenotypes of ALS almost results in misdiagnosis, whilst early and accurate ALS diagnosis is crucial for ensuring quick access to available pharmacologic and therapeutic options and early care planning [3]. ALS may be inherited in 5-10% of the whole population of ALS patients (fALS), so more than 90% of ALS patients are sporadic (sALS), without any family history. The most frequent genes involved in the development of ALS are as follows: C9orf72, SOD1, TARDBP, and FUS/TLS[4]. Despite the identification of several causative genes, the underlying pathogenic mechanisms of ALS are not well understood. Noteworthy, some ALS-associated genes, including TARDBP and FUS, encode RNA-binding proteins involved in miRNA processing [5] and signify the role of miRNAs in the pathophysiology of ALS.

MiRNAs are small (18-25 nucleotides long), endogenous, non-coding RNAs that post-transcriptionally regulate protein-coding mRNAs. The non-coding RNAs have been found to play a vital role in several diseases, including cancers and neurodegenerative diseases [6]. Recently, miRNAs are of great interest as a potential diagnostic and prognostic biomarker in several conditions. In terms of ALS, it is frequently reported that miRNAs participate in various molecular pathways associated with neurodegenerative development [2].
Research barriers for identifying molecular pathways of ALS include small sample size, using monogenic animal models, or human tissue from autopsy at the end stage of neuron degeneration. Because access to nervous tissue in life is not ethically acceptable, a circulating molecular signature has been considered [7]. Pieces of evidence have shown circulating microRNAs, and gene expression can be used to monitor neurological diseases, including ALS [8]. Recently, some review studies analyzed researches that previously identified differentially expressed miRNAs in ALS patients [9-11]. Despite a large number of studies, no systems biology-based analysis has been performed to ascertain ALS-related miRNAs. Indeed, there are multiple circulating miRNA profiling studies in ALS, but a poor overlap exists between miRNAs reported as deregulated in the high throughput screening studies [12].

Here, to minimize the effect of heterogeneity among ALS patients and applied platforms, we performed a systematically meta-analysis via a robust method aggregating the results of studies comparing circulating miRNA profiles of ALS patients and controls over the 2012-2019 period. Also, we enriched the potential target genes to provide insights into pathological mechanisms of ALS. Further, protein-protein interaction (PPI) networks were established to characterize essential genes that possibly correlate with ALS disease. Finally, we experimentally verified the results of the miRNA meta-analysis.

Materials And Methods

The workflow for the overall procedure is shown in Fig. 1.

Systematically meta-analysis

Literature search strategy

To identify miRNA expression profiling studies in ALS, we performed a search strategy as follows; we systematically searched the literature in PubMed (www.ncbi.nlm.nih.gov/pubmed/), Scopus (www.scopus.com), and EMBASE (www.embase.com) databases published up to 30 June 2020. We used search term TITLE-ABS-KEY ((miRNA* OR microRNA* OR mir-*) and (ALS OR Amyotrophic Lateral Sclerosis)) from article titles, abstracts, and keywords; by the way, we screened all references of relevant studies for additional studies. We also contacted the authors when the needed data were not available.

Eligibility criteria

We carefully assessed the titles and abstracts of each article and the full text of eligible studies. The inclusion criteria were: 1) original case-control studies in humans comparing the circulating miRNA expression between sALS patients and healthy control subjects; 2) employing miRNA expression profiling by using miRNA microarray, next-generation sequencing (NGS) or qRT-PCR; 3) reporting the separated lists of up- and/or down-regulated miRNAs according to respective cut-off criteria; 4) publishing in the English language. The exclusion criteria were: 1) studies that conducted on animal models or cell lines; 2)
articles that evaluated only a few preselected miRNAs or a set of preselected miRNAs; 3) studies that did not focus on sporadic ALS, but just other types such as familial ones; 4) studies that evaluated miRNA expression in samples other than blood, such as muscles, brain and spinal cord; 5) studies that did not report complete lists of up- and/or down-regulated miRNA which were not available even after screening microarray datasets and contacting with authors; 6) review articles and case reports; 7) articles not reporting fold changes or $p$-value for differentially expressed miRNAs.

All full-text articles were carefully reviewed and the following items were collected from the eligible studies: first author, date of publication, the origin of study, number of samples, number of probes, profiling assay, and cut-off criteria. The lists of significant differentially expressed miRNAs were extracted from the studies. If the list (or full list) was not available in the article or supplementary appendices, we requested data. Where necessary, miRBase version 21 was used to obtain the standard name of miRNAs.

**Robust rank aggregation analysis**

We used “RobustRankAggreg” package in R software (available in the comprehensive R Archive Network website, http://cran.r-project.org/) to identify meta-signature miRNAs in sALS patients. The Robust Rank Aggregation (RRA) method normalizes the ranked miRNAs and assigns a significance score to each miRNA. The probabilistic model makes the algorithm free and robust to outliers, noise, and errors [12]. Then, this method is a powerful and compelling approach for the identification of differentially expressed miRNA signature, and we utilized it for recording and ranking the lists of normalized up- and down-regulated miRNAs by using their fold change. A Bonferroni correction was performed to reduce false-positive results.

**Prediction of target genes of meta-signature miRNAs in sALS using online database**

The R-based multiMiR package ver.2.3.0 (http://multimir.ucdenver.edu) was retrieved to predict targets of meta-signature miRNAs. This package is a comprehensive collection of predicted and validated miRNA-target interactions and their associations with diseases and drugs. The multiMiR enables retrieval of miRNA-target interactions from 11 external databases to predict targets of miRNAs by TargetScan, DIANA-microT, EIMMo, miRDB, miRanda, MicroCosm, PicTar, and PITA databases. Furthermore, validated targets of miRNAs were acquired from miRTarBase, TarBase, and miRecords databases. We searched the top 35% among all conserved and nonconserved target sites and selected only targets predicted by at least three algorithms or validated by one database for further analyses [13].

**Pathway analysis of significant microRNA target genes**
In order to clarify the biological processes related to the identified targets, gene set enrichment was performed using Enrichr (http://amp.pharm.mssm.edu/Enrichr/) through its web interface. The Enrichr tool calculates $p$-values using a Fisher's exact test and adjusts $p$-values using the Benjamini-Hochberg method to correct for multiple hypotheses testing [14]. In this study, gene set enrichment analyses were done against the following databases: Kyoto Encyclopedia of Genes and Genomes pathway (KEGG), Panther, and BioCarta enriched pathway. Further on, Gene Ontology (GO) analysis of differentially expressed miRNA targets was conducted using the ClueGO version 2.0.7 app in Cytoscape [15]. ClueGO platform can analyze and visualize interrelations of terms and functional groups in biological networks based on the hypergeometric distribution. In this study, a $p$-value of <0.05 and a kappa coefficient of 0.4 was considered as threshold values. To correct the $p$-values for multiple testing, Bonferroni step-down was used.

**Protein-protein interaction network analysis for microRNA target genes**

PPI networks represent a model of interaction among gene pairs to explore disorder-related genes. In the present study, network analysis was performed using a more limited number of genes, whereby, we searched circulating gene expression profiling studies in sALS patients according to the criterion applied for miRNA expression profiling studies. Then, we extracted up-regulated genes and intersected the list with putative targets of meta-signature miRNAs.

PPI Network construction for selected genes was performed using the online search tool for the retrieval of interacting genes (STRING) database version 11. [16]. Parameters were set to default. The network was subsequently imported into Cytoscape version 3.8 for further visualization and analysis. The Cytoscape app MCODE (molecular complex detection) version 1.6 was used to identify highly interconnected subclusters of proteins within the PPI network using a degree cut-off of 2, a node score cut-off of 0.2, a K-core of 2, and a maximum depth of 100 [17].

The PPI data were then exported to CytoHubba (version 0.1), a Java app for Cytoscape. CytoHubba was used to give some insight into the most influential nodes in the network by 11 topological algorithms [18]. Among all the algorithms, MCC (Maximal Clique Centrality) has a better performance in predicting essential nodes in the PPI network. The top 10 nodes ranked by MCC were employed to identify the sALS hub genes in this meta-analysis.

**Real-time quantitative reverse transcription (RT-qPCR)**

Results obtained from the meta-analysis were validated by performing TaqMan Real-time qPCR in plasma specimens of sALS and control subjects. miRNAs are presented in the cell-free form of biofluids, including plasma. Plasma biomarkers are of interest because they are non-invasive and non-expensive. ALS patients without any family history of ALS and other neurodegenerative disorders were enrolled in
this study. All patients were neurologically evaluated using El-Escorial criteria and 30 patients with definite or probable ALS were selected. Also, 30 age- and sex-matched non-relevant healthy controls participated in this study. All affected and control individuals were informed of the nature of the research and consent form signed. This research was performed in accordance with the Declaration of Helsinki and with approval of the ethics board of the Iran University of Medical Science. Peripheral blood samples (3 mL) were collected from patients and controls under a fasting state and drawn into EDTA tubes. Within 3-4 h, the tubes were subjected to centrifugation at 200 ×g for 10 min. Next, 1 mL aliquots of the plasma were transferred to 1.5 mL tubes and centrifuged at 10,000 ×g for 10 min at 4 °C to remove contamination or cellular debris. The supernatant was collected and stored at -80 °C until use. The total RNA was extracted using TRIzol reagent (Invitrogen). The corresponding cDNAs were synthesized using ExcelRT Reverse Transcriptase (SMOBIO) according to the manufacturer's protocol. PCR amplification for TaqMan qPCR was performed using High-Rox 2x Master Mix for Probe. RT-PCR reaction was conducted in a Corbett Rotor-Gene 6000 HRM Real-time PCR machine. The relative quantities of miRNAs in the cases and controls were calculated via the $2^{-\Delta \Delta CT}$ method. Each experiment was in duplicate. Comparison of groups was performed using Mann–Whitney U-test and $p$-value < 0.05 was considered significant. Ultimately, Receiver operating characteristic (ROC) analysis was performed to evaluate the diagnostic value of differentially expressed miRNA. The area under ROC curve (AUC) implies the average value of sensitivity (true positive percentage) for all possible values of specificity (false positive percentage).

**Results**

**Systematically meta-analysis for finding meta-signature miRNAs in sALS**

**Literature search and included studies**

The strategy used to include in this meta-analysis was demonstrated in the flow diagram (Supplementary Fig. S1). Briefly, 1355 possible eligible studies published between the years 1997 and 2019 were obtained in Pubmed, Scopus, and EMBASE databases considering our criteria. After eliminating duplicated publications, reviews, and unrelated studies such as studies considering ALS patients other than sALS and also the studies profiled non-circulating miRNAs, 55 articles met the eligibility. Finally, following full-text analysis, 12 articles used the whole miRNome profiling approach included in this meta-analysis [7, 19-29]. Supplementary Table S1 provides the main information of each included study.

**Meta-signature miRNAs in sALS patients**

In our pooled datasets including 12 miRNA expression profiling studies, 219 miRNAs were reported to be differentially expressed in groups of 206 sALS patients and 181 healthy controls. Among 265 miRNAs, 167 were down-regulated and 98 were up-regulated. Furthermore, 29 miRNAs were reported in at least two
studies. We applied the novel robust rank aggregation (RRA) method to identify consistently differentially expressed miRNAs across the profiles (Table 1). After using the RRA method, we identified 14 miRNAs (5 upregulated and 9 downregulated) with \( p \)-value < 0.05 among which, two downregulated miRNAs (hsa-miR-451a and hsa-let-7f-5p) were statistically significant meta-signature (Adj. \( p \)-value < 0.05).

**Predicting the putative targets of meta-signature miRNAs**

Bioinformatic analysis was performed to retrieve the putative target genes of hsa-miR-451a and hsa-let-7f-5p. The integration of eight predicted and three validated databases were systematically screened by using the multiMiR R package for miRNA–target interactions. 1,617 target genes were obtained according to our criterion. It’s noteworthy that all bioinformatic analyses were accomplished only for meta-signature miRNAs.

**The enrichment analysis for putative target genes**

Following the enrichment analysis by web-based Enrichr software, it was detected the most significantly enriched KEGG terms on sALS is “FoxO signaling pathway”. A KEGG pathway analysis also revealed 69 other pathways overrepresented in the putative targets of hsa-let-7f-5p and hsa-miR-451a, including “MAPK signaling pathway”, “PI3K-Akt signaling pathway”, “Amyotrophic lateral sclerosis” and “apoptosis”. Panther 2016 displayed the meta-signature miRNAs target genes are mostly associated with “Apoptosis signaling pathway”. As well, BioCarta 2016 revealed a relationship between the “MAPKinase Signaling Pathway” and the predicted targets (Supplementary Table S2). Several databases analyzed by Enrichr (KEGG, Panther, BioCarta) revealed a relationship between the FoxO, MAPK, and apoptosis signaling pathways with the putative targets of hsa-let-7f-5p and hsa-miR-451a. Fig. 2 demonstrates multiple overlapping pathways presented as the most significantly enriched terms in the three databases. MAPK1/ERK2, MAPK8/JNK, CHUK/IKKa, and IKBKB/IKKb are common genes in three pathways. The results of gene ontology enrichment through ClueGO revealed in terms of “biological process” and “molecular function”, targets of let-7f-5p and miR-451a mainly involved in “protein serine-threonine kinase activity”, “anatomical structure morphogenesis”, “negative regulation of translation”, “cellular response to stress”, “metal ion binding” and “macromolecule metabolic process” (Supplementary Fig. S2).

**PPI network establishment and hub gene identification**

To conduct a much stricter approach, we systematically reviewed studies that have profiled circulating gene expression in sALS according to the criterion applied for the systematic review of miRNA studies. We found seven studied between 2009 to 2019 (Supplementary Table S3). Since both differentially expressed meta-signature miRNAs are downregulated, the targets are expected to be upregulated because of the degradation effect of miRNAs. So, we considered only upregulated differentially expressed genes in the studies. By intersecting the putative targets of meta-signature miRNAs and the upregulated genes in profiling studies, 241 candidate genes were obtained and were used to build the corresponding PPI
networks. Genes were uploaded to STRING. There were 338 edges and 238 nodes in the PPI network (PPI enrichment \( p \)-value: 0.000556, an average local clustering coefficient: 0.429, average node degree: 2.84). Cytoscape software was applied to visualize the interactive gene relationships. Degrees \( >10 \) were considered the criterion of judgment. A total of 10 genes were identified as hub genes with Cytoscape: \textit{TP53}, \textit{STAT3}, \textit{CXCL8}, \textit{CASP3}, \textit{IL10}, \textit{CDC34}, \textit{IKBKB}, \textit{TNFSF10}, \textit{FAS}, \textit{FBXL20} (Fig. 3a). The PPI data imported into Cytoscape software were analyzed by CytoHubba, an app of Cytoscape to predict important nodes or sub-networks in the network. The top 10 hub genes were selected based on the MCC algorithm in cytoHubba (Fig. 3b). We further utilized the MCODE to detect clusters, which are highly interconnected regions in a network. By using MCODE, seven network clusters (modules) were detected (Supplementary Table S4). The first cluster, MCODE1, with 19 nodes, 76 edges, and a cluster score of 8.444 was selected for GO enrichment and determining hub genes (Fig. 3c-d). The most significant GO terms over-represented by the hub genes associated with “positive regulation of gene silencing by miRNA”, “positive regulation of release of cytochrome C from mitochondria”, “cysteine-type endopeptidase activity involved in apoptotic signaling pathway”, “regulation of extrinsic apoptotic signaling pathway via DDRs (DNA damage response)” and “positive regulation of neuron apoptotic process”.

**Validation of the identified miRNAs in plasma of sALS and healthy control subjects**

In order to verify the results of the meta-analysis, we evaluated the relative expression of miR-451a, let-7f-5p, and two top-ranked upregulated miRNAs (miR-338-3p and miR-34a-5p) using TaqMan RT-qPCR in 30 sALS and 30 control subjects (16 men and 14 women in each group). The median age of patients and controls was 55.4±12 and 54.4±10 years, respectively.

Relative expression values were normalized to Cel-miR-39-3p. The primers were listed in Supplementary Table S5. RT-qPCR results demonstrated the expression of let-7f-5p was significantly downregulated (fold change=0.25, \( p \)-value=2.83e-4) in sALS patients comparing to healthy controls; whereas, miR-451a downregulated but not significantly (Fig. 4a-b). The miR-451a is erythrocyte specific, and its relative expression can be used as an indicator of hemolysis in serum and plasma samples [30]. Noteworthy, previous studies have revealed the fragility of red cells and a high degree of hemolysis in plasma samples from ALS patients [31]. Therefore, plasma and serum specimens are not appropriate for evaluation of erythrocyte-specific miRNAs such as miR-451, miR-16 and etc. in ALS disease. As noted before, miR-451a was downregulated in blood cells, so it didn’t show significantly differential expression in plasma. According to the results of experimental phase, miR-338-3p was significantly upregulated (fold change =4.38, \( p \)-value=4.66e-3) in sALS patients relative to controls. The expression of miR-34a-5p was not significantly differentiated (Supplementary Table 6).

ROC analysis was conducted to assess the sensitivity and specificity of the let-7f-5p and miR-338-3p as plasma biomarkers for ALS. The AUC values were 0.78 and 0.77, respectively, indicating both let-7f-5p
and miR-338-3p have an acceptable diagnostic efficacy (Fig. 5).

**Discussion**

The identification of a molecular signature for amyotrophic lateral sclerosis is quite an intriguing yet challenging arena. Nevertheless, since obtaining tissue biopsies is the main limitation in studies of neurodegenerative diseases, tissue-based markers are not an applied option for early detection of ALS disease. Thus, this study aimed to explore circulating disease-specific markers that would be beneficial for diagnosis and treatment strategies in ALS. By targeting multiple transcripts and affecting the expression of numerous proteins, miRNAs play a crucial role in cellular functions [32]. Researches in miRNA expression patterns and high-throughput profiling have resulted in exploring novel biomarkers. However, limitations such as small sample size, using different platforms, various threshold criteria are some obstacles in getting a consensus to select miRNAs as biomarkers. To overcome the obstacles, a meta-analysis method by aggregating and comparing multiple ranked miRNA lists (RRA) has been designed and applied in several studies. In the present study, using the RRA method, two downregulated miRNAs (hsa-miR-451a and hsa-let-7f-5p) were found to have significant diagnostic potential. To predict the biological function of the miRNAs, their target genes were evaluated via bioinformatics analysis.

The gene encoding miR-451a, located in chromosomal region 17q11.2, plays a vital role in normal biological process and pathological condition. It has been mentioned miR-451a could protect cells against apoptosis induced via ischemia/reperfusion (I/R) injury and oxidative stress. MiR-451a overexpression causes to increase superoxide dismutase activity that leads to a decrease in neuron death [33]. Additionally, miR-451a protects erythrocytes from oxidative stress. Downregulation of miR-451a causes accumulation of 14-3-3ζ that leads to inhibition of FoxO3 activity [34]. MiR-451a is also involved in the neuroinflammation process [8]. According to the present systematic review, miR-451a was downregulated in leukocytes and peripheral blood of ALS patients [7, 22, 27, 28]. Besides, downregulation of this miRNA is also reported as a blood biomarker in Parkinson's disease (PD) [35].

The let-7 family, as one of the first identified miRNAs, is highly conserved in sequence and function across species. They are known to be essential for development and viability [36]. Let-7 is regulated during the cell cycle; meantime regulates cell cycle dynamics. In developing brain, let-7 promotes differentiation by suppressing genes of proliferation. The expression of let-7 decreases with advanced aging [37]. Deregulation of their expression causes several diseases including neurodegenerative disease. [38]. It has been demonstrated let-7 upregulation impairs glucose homeostasis and leads to neuron death, while its downregulation results in cancer. The human let-7 miRNA family comprises nine mature members with strong sequence similarity [36]. Variation exists in the GU-rich sequences, but not in the seed sequence. Let-7f-5p is located in the intergenic region at 9q22.3 and is reported to involve in a series of physiological and pathological processes [39]. Aberrant expression of let-7f has reported in several cancers. Previous studies also have provided evidence of decreasing expression of let-7f in multiple sclerosis (MS) and Alzheimer's diseases (AD) [39, 40]. As presented in the systematic review, let-
7f-5p expression was significantly downregulated in the peripheral blood, serum, plasma, and CSF of ALS patients [19, 20, 24, 26, 28].

Functional enrichment analysis of miR-451a and let-7f targets revealed regulation via various pathways, including “FoxO signaling pathway”, “MAPK signaling pathway” and “apoptosis”. Apoptosis and MAPK signaling pathways are known in ALS [41]. Mitogen-activated protein kinases (MAPKs) are serine–threonine protein kinases that regulate various cellular activities including proliferation, differentiation, apoptosis, survival, and inflammation. Protein kinases have also been found to play key roles in several neurodegenerative diseases such as PD, AD, and ALS. MAPKs comprise c-Jun NH2-terminal kinase (JNK), p38 MAPK, and extracellular signal-regulated kinase (ERK), each of which exists in several isoforms [42]. In various signaling pathways, MAP Kinases are involved as central incorporating. Proinflammatory cytokines and nitric oxide production in motor neurons and glial cells activate the p38 MAPK signaling pathway that plays a critical role in the propagation of environmental toxic among adjacent neuron cells, relatively rapid progression of ALS and eventually neuron death [43].

Apoptosis mediated by intracellular processes, has been defined as programmed cell death. In the developing brain, apoptosis is of need for elimination of excess neurons, yet neuronal apoptosis is the main pathomechanism in various neurodegenerative processes [44]. Apoptosis may be initiated through one of intrinsic or extrinsic signaling cascades, albeit both dependent on caspases (cysteine proteases) function. Molecular pathways of apoptosis are activated in amyotrophic lateral sclerosis. According to research results, scavenging apoptosis delays neuronal death and prolongs survival in ALS models. Despite the various interfering, eventually, these models die, indicating that targeting the apoptosis cascade can slow the death trend but cannot abolish it [45].

The FoxO family includes four transcription factors; FoxO1, FoxO3, FoxO4, FoxO6. Several upstream proteins regulate function and structure of FoxOs by post-translationally modification and affect subcellular localization and consequent transcription activity of them, i.e. they are downstream targets of the serine/threonine PKB/AKT. The AKT regulates processes related to cellular proliferation and survival during neurodegenerative disorders. It is worth noting that AKT is a validated target of miR-451a.

Downstream, FoxOs regulate the expression of various genes, afterward control several cascades, and eventually alter cellular function. In particular, FoxOs are involved in pathogenesis of neurodegenerative disease. Yet, FoxOs and their downstream targets have protective effects on neuronal dysfunction [46]. FoxOs, especially FoxO1 and FoxO3 are necessary for neuronal protection during aging. Strikingly, they are essential for neutralizing proteotoxic and oxidative stresses and preventing the accumulation of insoluble protein aggregates. In response to stress, foxOs may either trigger neuronal death or survival cascades [47].

Here, in circulating meta-analyzed studies, FoxOs were not part of differentially expressed genes, albeit they reported as differentially expressed in ALS spinal cords [48, 49]. Additionally, recent studies have indicated potential roles for FoxOs in the pathogenesis of ALS. According to the studies result, the FoxO pathway is activated during ALS to protect against ALS related pathogenesis. Larger et al. found a
significant up-regulation of atrogin-1 in ALS skeletal muscles that correlate with a decreasing AKT. Although they saw no difference in FoxO1 and FoxO3 levels between patient and control groups, the results of the study implied that inhibition of AKT induces FoxO activity by decreasing cytosol sequestration [50]. Han et al. reported that a decrease in expression of neuronal vMSP, a cleavage product of VAPB, due to mutation of VAPB/ALS8 in ALS, triggers FoxO activation, increases ATP levels, and prolongs survival in VAPB C. elegans mutants. [51]. Zhang et al. have revealed in proteotoxic stress conditions; TDP-43 translocated to cytoplasm and relieved an inhibition on FoxO’s transcription activity in the nucleus. In cytoplasm, TDP-43 competes with FoxOs for binding to proteins 14-3-3 and consequently promotes the nuclear translocation and activation of FoxOs. The activation of FoxO transcription factors, including FoxO1 and FoxO3 induces autophagy, and in the case of FoxO3a, proteasome activity [52]. However, during chronic stress such as neurodegenerative trend, the potential of TDP-43 for defending the stress would be lost through lack of TDP-43 action resetting. Further, the overactivity of FoxOs led to cell death [53]. More recently, Watts et al. have reported suppression of MAP4K4 retains motor neuron viability by alleviating c-Jun induced apoptosis and FoxO mediated autophagy through decreasing protein aggregates in ALS [41]. On the other hand, activation of MAP4K4, a predicted target of let-7f, promotes degeneration of motor neurons. Phosphorylation of MAP4K4 due to cellular stress leads to phosphorylation of JNK and then c-Jun, results in apoptosis [54]. Regarding motor neurons, it has shown FoxO3a play a role to determine stress response. In response to growth factor deprivation, PI3K/AKT, one of the central regulators of FoxO transcriptional activity, decreases. Then, FoxO3a translocate from cytoplasm to nucleus and induces apoptosis through activation of Fas/Fasl and JNK pathways [55]. So, though, the role of FoxO signaling pathway is not well specified in ALS disease, previous studies have revealed dysfunction of FoxOs is contributed to pathogenesis of ALS. Activated FoxO signaling may protect motor neurons against ALS associated degeneration or drive the neuron to death. So, it needs further investigations of FoxO interactions and identifying targets involved in protective effects. Indeed, in addition to mechanisms regulating expression, post-translational modifications of FoxOs are important in pathogenesis of ALS.

Protein–protein interaction points out the interplay between two or more proteins as a response to various disorders and perturbations. They are essentially dynamic and allows cells to attune to different stimuli and environmental conditions. Disturbing such an interconnected system can have serious consequences, such as producing disease phenotypes. Hence PPI analysis has excellent helpful hints for identifying proteins that play an effective role in the disease [56]. In this study, a PPI network was conducted with the STRING database. Applying the Cytoscape app cytoHubba, the top ten hub genes contributing to ALS were predicted. Further, we used MCODE to discover the core module in the PPI network. Ontology analysis of proteins involved in cluster1 indicates predicted target genes of let-7f and miR-451a, that meanwhile up-regulated in ALS patients, are enriched in neuron apoptosis, gene silencing by miRNA, and multiple cascades of apoptosis. Our results provide independent support for findings obtained from meta-signature miRNA analysis and suggest that their targets involved in the PPI analysis are key factors in the pathogenesis of ALS. Although the results of RT q-PCR didn’t present significantly downregulation of miR-451a in the plasma of ALS patients, as described above, plasma is not an
appropriate specimen for indicating miR-451a differential expression. Indeed, blood cells including leukocytes are better for detecting the differential expression. Besides these downregulated meta-signature miRNAs, two top-ranked miRNAs; miR-338-3p and miR-34a-5p, were experimentally verified in this study. The results demonstrated miR-338-3p is upregulated in plasma of sALS patients. The miR-338-3p, located at chromosome 17q25.3 was first reported in prion-induced neurodegeneration. Previous studies revealed the miRNA consistently upregulated in CSF, serum, leukocytes, and spinal cord of sALS patients [57]. Furthermore, it is reported that miR-338-3p was upregulated in neuromuscular junction of patients with sporadic ALS [27]. miR-338-3p is involved in several biological pathways that could contribute to ALS pathogenesis, including neurodegeneration and apoptosis. Several genes associated with ALS including ARHGEF28 and VAPB are the targets of miR-338-3p. ARHGEF28, a novel ALS gene involved in the aggregation of light neurofilaments, is a validated target for miR-338-3p [58]. Also, a miR-338-3p predicted target, VAPB, is recently suggested as a diagnostic biomarker in ALS that complicated in ER-associated aggregates [59]. More recently, Song et al. reported Fox03a induces miR-338-3p expression and may play a critical role in decreasing cell survival through directly suppressing the expression of NRP1 [60].

Conclusion

In summary, this study demonstrated that let-7f-5p and miR-338-3p are suitable circulating biomarkers for ALS. Certainly, they can be easily accessed from patient plasma. Further, beyond the known pathways such as MAPK signaling and apoptosis, the FoxO signaling pathway is involved in ALS pathogenesis via multiple cascades.

Declarations

Funding

This work is supported by the Medical Research Council of Iran University of Medical Sciences (grant number 4286).

Conflict of interest

All authors claim absence of financial interests and absence of conflict of interest.

Availability of data

Data will be made available on request.

Code availability

Not applicable

Author contributions
ND: searching the literature, meta-analysis, bioinformatics analysis, RNA extraction, real-time qPCR, writing the manuscript; MTJ: study design and supervision of the research; MM: study design; AA: searching the literature, meta-analysis, data analysis; MB: primer design, real-time qPCR; ST: genetic advisor, BZ: clinical evaluations and supervision of the research. All authors revised the manuscript and approved it for submission.

**Compliance with ethical standards**

The study protocol conformed to the guidelines of the Ethics Committee of the Iran University of Medical Science (IR.IUMS.REC 1395.9221559202)

**Consent to participate**

All patients and control subjects signed an informed consent form to participate.

**Consent for Publication**

All patients and control subjects signed an informed consent form to publish.

**Acknowledgments**

We sincerely thank all the staff of the Cellular and Molecular Research Center. We especially appreciate Hossein Safarpour and HamidReza Moazzeni for their cooperation in bioinformatics analysis.

**References**

1. Cleveland DW, Rothstein JD (2001) From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nature reviews neuroscience 2(11):806–819
2. Ricci C, Marzocchi C, Battistini S (2018) MicroRNAs as biomarkers in amyotrophic lateral sclerosis. Cells 7(11):219
3. Hogden A, Foley G, Henderson RD, James N, Aoun SM (2017) Amyotrophic lateral sclerosis: improving care with a multidisciplinary approach. Journal of multidisciplinary healthcare 10:205
4. Rinchetti P, Rizzuti M, Faravelli I, Corti S (2018) MicroRNA metabolism and dysregulation in amyotrophic lateral sclerosis. Mol Neurobiol 55(3):2617–2630
5. Kawahara Y, Mieda-Sato A. TDP-43 promotes microRNA biogenesis as a component of the Drosha and Dicer complexes. Proceedings of the National Academy of Sciences. 2012;109(9):3347-52
6. Talebi F, Ghorbani Gazar S (2013) Role of microRNAs in Central Nervous System Development. The Neuroscience Journal of Shefaye Khatam 1(3):17–22
7. De Felice B, Guida M, Guida M, Coppola C, De Mieri G, Cotrufo R (2012) A miRNA signature in leukocytes from sporadic amyotrophic lateral sclerosis. Gene 508(1):35–40
8. Ravnik-Glavac M, Glavac D (2020) Circulating RNAs as Potential Biomarkers in Amyotrophic Lateral Sclerosis. Int J Mol Sci 21(5):1714
9. Dardiotis E, Aloizou A-M, Siokas V, Patrinos GP, Deretzi G, Mitsias P et al (2018) The role of microRNAs in patients with amyotrophic lateral sclerosis. J Mol Neurosci 66(4):617–628
10. Foggin SA, Dajas-Bailador F, Mesquita-Ribeiro R, Layfield R (2019) Biological significance of microRNA biomarkers in ALS—innocent bystanders or disease culprits? Front Neurol 10:578
11. Joilin G, Leigh PN, Newbury SF, Hafezparast M (2019) An overview of MicroRNAs as biomarkers of ALS. Front Neurol 10:186
12. Kolde R, Laur S, Adler P, Vilo J (2012) Robust rank aggregation for gene list integration and meta-analysis. Bioinformatics 28(4):573–580
13. Ru Y, Kechris KJ, Tabakoff B, Hoffman P, Radcliffe RA, Bowler R et al (2014) The multiMiR R package and database: integration of microRNA–target interactions along with their disease and drug associations. Nucleic acids research 42(17):e133-e
14. Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z et al (2016) Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic acids research 44(W1):W90–W97
15. Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A et al (2009) ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 25(8):1091–1093
16. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J et al (2019) STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic acids research 47(D1):D607–D613
17. Bader GD, Hogue CW (2003) An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinform 4(1):2
18. Chin C-H, Chen S-H, Wu H-H, Ho C-W, Ko M-T, Lin C-Y (2014) cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC systems biology 8(S4):S11
19. Butovsky O, Siddiqui S, Gabriely G, Lanser AJ, Dake B, Murugaiyan G et al (2012) Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J Clin Invest 122(9):3063–3087
20. Takahashi I, Hama Y, Matsushima M, Hirotani M, Kano T, Hohzen H et al (2015) Identification of plasma microRNAs as a biomarker of sporadic Amyotrophic Lateral Sclerosis. Mol Brain 8(1):67
21. Freischmidt A, Müller K, Zondler L, Weydt P, Mayer B, von Arnim CA et al (2015) Serum microRNAs in sporadic amyotrophic lateral sclerosis. Neurobiol Aging 36(9):2660. e15-. e20
22. Chen Y, Wei Q, Chen X, Li C, Cao B, Ou R et al (2016) Aberration of miRNAs expression in leukocytes from sporadic amyotrophic lateral sclerosis. Front Mol Neurosci 9:69
23. Benigni M, Ricci C, Jones AR, Giannini F, Al-Chalabi A, Battistini S (2016) Identification of miRNAs as potential biomarkers in cerebrospinal fluid from amyotrophic lateral sclerosis patients. Neuromol Med 18(4):551–560
24. Waller R, Wyles M, Heath PR, Kazoka M, Wollff H, Shaw PJ et al (2018) Small RNA sequencing of sporadic amyotrophic lateral sclerosis cerebrospinal fluid reveals differentially expressed miRNAs related to neural and glial activity. Front NeuroSci 11:731

25. Waller R, Goodall EF, Milo M, Cooper-Knock J, Da Costa M, Hobson E et al (2017) Serum miRNAs miR-206, 143-3p and 374b-5p as potential biomarkers for amyotrophic lateral sclerosis (ALS). Neurobiol Aging 55:123–131

26. Raheja R, Regev K, Healy BC, Mazzola MA, Beynon V, Von Glehn F et al (2018) Correlating serum microRNAs and clinical parameters in amyotrophic lateral sclerosis. Muscle Nerve 58(2):261–269

27. De Felice B, Manfettoto F, Fiorentino G, Annunziata A, Biffali E, Pannone R et al (2018) Wide-ranging analysis of microRNA profiles in sporadic amyotrophic lateral sclerosis using next-generation sequencing. Frontiers in genetics 9:310

28. Liguori M, Nuzziezzo N, Introna A, Consiglio A, Licciulli F, D’Errico E et al (2018) Dysregulation of MicroRNAs and target genes networks in peripheral blood of patients with sporadic amyotrophic lateral sclerosis. Front Mol Neurosci 11:288

29. Katsu M, Hama Y, Utsumi J, Takashina K, Yasumatsu H, Mori F et al (2019) MicroRNA expression profiles of neuron-derived extracellular vesicles in plasma from patients with amyotrophic lateral sclerosis. Neurosci Lett 708:134176

30. Blondal T, Nielsen SJ, Baker A, Andreasen D, Mouritzen P, Teilum MW et al (2013) Assessing sample and miRNA profile quality in serum and plasma or other biofluids. Methods 59(1):S1–S6

31. Ronnevi LO, Conradi S (1984) Increased fragility of erythrocytes from amyotrophic lateral sclerosis (ALS) patients provoked by mechanical stress. Acta neurologica scandinavica 69(1):20–26

32. Shioya M, Obayashi S, Tabunoki H, Arima K, Saito Y, Ishida T et al (2010) Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3. Neuropathology applied neurobiology 36(4):320–330

33. Liu Q, Hu Y, Zhang M, Yan Y, Yu H, Ge L (2018) microRNA-451 protects neurons against ischemia/reperfusion injury-induced cell death by targeting CELF2. Neuropsychiatric Disease Treatment 14:2773

34. Menon V, Ghaffari S (2018) Transcription factors FOXO in the regulation of homeostatic hematopoiesis. Curr Opin Hematol 25(4):290

35. Schulz J, Takousis P, Wohlers I, Itua IO, Dobricic V, Rücker G et al (2019) Meta-analyses identify differentially expressed microRNAs in Parkinson's disease. Ann Neurol 85(6):835–851

36. Roush S, Slack FJ (2008) The let-7 family of microRNAs. Trends in cell biology 18(10):505–516

37. Fairchild CL, Cheema SK, Wong J, Hino K, Simó S, La Torre A (2019) Let-7 regulates cell cycle dynamics in the developing cerebral cortex and retina. Scientific reports 9(1):1–21

38. Kumar L, Haque R, Nazir A (2016) Role of microRNA Let-7 in modulating multifactorial aspect of neurodegenerative diseases: An overview. Mol Neurobiol 53(5):2787–2793
39. Li Z-H, Wang Y-F, He D-D, Zhang X-M, Zhou Y-L, Yue H et al (2019) Let-7f-5p suppresses Th17 differentiation via targeting STAT3 in multiple sclerosis. Aging 11(13):4463
40. Han L, Zhou Y, Zhang R, Wu K, Lu Y, Li Y et al (2018) MicroRNA Let-7f-5p promotes bone marrow mesenchymal stem cells survival by targeting caspase-3 in alzheimer disease model. Front NeuroSci 12:333
41. Watts ME, Wu C, Rubin LL (2019) Suppression of MAP4K4 Signaling Ameliorates Motor Neuron Degeneration in Amyotrophic Lateral Sclerosis-Molecular Studies Toward New Therapeutics. Journal of Experimental Neuroscience 13:1179069519862798
42. Kim EK, Choi E-J (2015) Compromised MAPK signaling in human diseases: an update. Arch Toxicol 89(6):867–882
43. Mitra J, Hegde PM, Hegde ML (2019) Loss of endosomal recycling factor RAB11 coupled with complex regulation of MAPK/ERK/AKT signaling in postmortem spinal cord specimens of sporadic amyotrophic lateral sclerosis patients. Mol Brain 12(1):55
44. Toku K, Tanaka J, Yano H, Desaki J, Zhang B, Yang L et al (1998) Microglial cells prevent nitric oxide-induced neuronal apoptosis in vitro. J Neurosci Res 53(4):415–425
45. Vila M, Przedborski S (2003) Targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci 4(5):365–375
46. Hu W, Yang Z, Yang W, Han M, Xu B, Yu Z et al (2019) Roles of forkhead box O (FoxO) transcription factors in neurodegenerative diseases: A panoramic view. Progress in neurobiology 181:101645
47. Santo EE, Paik J. FOXO in neural cells and diseases of the nervous system. Current topics in developmental biology. 127: Elsevier; 2018. p. 105 – 18
48. Andrés-Benito P, Moreno J, Aso E, Povedano M, Ferrer I (2017) Amyotrophic lateral sclerosis, gene deregulation in the anterior horn of the spinal cord and frontal cortex area 8: implications in frontotemporal lobar degeneration. Aging 9(3):823
49. Krach F, Batra R, Wheeler EC, Vu AQ, Wang R, Hutt K et al (2018) Transcriptome–pathology correlation identifies interplay between TDP-43 and the expression of its kinase CK1E in sporadic ALS. Acta Neuropathol 136(3):405–423
50. Léger B, Vergani L, Sorarù G, Hespel P, Derave W, Gobelet C et al (2006) Human skeletal muscle atrophy in amyotrophic lateral sclerosis reveals a reduction in Akt and an increase in atrogin-1. The FASEB journal 20(3):583–585
51. Han SM, El Oussini H, Scekic-Zahirovic J, Vibbert J, Cottie P, Prasain JK et al (2013) VAPB/ALS8 MSP ligands regulate striated muscle energy metabolism critical for adult survival in caenorhabditis elegans. PLoS Genet 9(9):e1003738
52. Zhao J, Brault JJ, Schild A, Goldberg AL (2008) Coordinate activation of autophagy and the proteasome pathway by FoxO transcription factor. Autophagy 4(3):378–380
53. Eijkelenboom A, Burgering BM (2013) FOXOs: signalling integrators for homeostasis maintenance. Nature reviews Molecular cell biology 14(2):83–97
54. Wu C, Watts ME, Rubin LL. MAP4K4 activation mediates motor neuron degeneration in amyotrophic lateral sclerosis. Cell reports. 2019;26(5):1143–1156. e5
55. Barthélémy C, Henderson CE, Pettmann B (2004) Foxo3a induces motoneuron death through the Fas pathway in cooperation with JNK. BMC Neurosci 5(1):1–9
56. Snider J, Kotlyar M, Saraon P, Yao Z, Jurisica I, Stagljar I (2015) Fundamentals of protein interaction network mapping. Molecular systems biology 11(12):848
57. De Felice B, Annunziata A, Fiorentino G, Borra M, Biffali E, Coppola C et al (2014) miR-338-3p is over-expressed in blood, CFS, serum and spinal cord from sporadic amyotrophic lateral sclerosis patients. Neurogenetics 15(4):243–253
58. Chou C-H, Shrestha S, Yang C-D, Chang N-W, Lin Y-L, Liao K-W et al (2018) miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions. Nucleic acids research 46(D1):D296–D302
59. Cadoni MPL, Biggio ML, Arru G, Secchi G, Orrù N, Clemente MG et al (2020) VAPB ER-Aggregates, A Possible New Biomarker in ALS Pathology. Cells 9(1):164
60. Song Y, Zeng S, Zheng G, Chen D, Li P, Yang M et al. FOXO3a-driven miRNA signatures suppresses VEGF-A/NRP1 signaling and breast cancer metastasis. Oncogene. 2020:1–14

Table

Table 1: Meta-signature miRNAs in sALS patients.

| miRNAs         | P-value | Adjusted P-value | Count | Trend |
|----------------|---------|------------------|-------|-------|
| hsa-miR-451a   | 2.15E-06| 0.005549         | 4     | Down  |
| hsa-let-7f-5p  | 1.89E-05| 0.048744         | 5     | Down  |
| hsa-miR-26b-5p | 0.001058| 1                | 3     | Down  |
| hsa-miR-16-5p  | 0.015687| 1                | 2     | Down  |
| hsa-miR-183-5p | 0.016547| 1                | 2     | Down  |
| hsa-miR-26a-5p | 0.022407| 1                | 3     | Down  |
| hsa-let-7a-5p  | 0.026115| 1                | 4     | Down  |
| hsa-miR-223-3p | 0.02625 | 1                | 2     | Down  |
| hsa-miR-148a-3p| 0.029116| 1                | 2     | Down  |
| hsa-miR-338-3p | 0.009681| 1                | 2     | Up    |
| hsa-miR-34a-5p | 0.011995| 1                | 2     | Up    |
| hsa-miR-23b-3p | 0.012927| 1                | 2     | Up    |
| hsa-miR-4736   | 0.038918| 1                | 1     | Up    |
| hsa-miR-224-3p | 0.03907 | 1                | 1     | Up    |
Figures

Figure 1

Overview of the study design.
Figure 2

Multiple overlapping pathways identified using Enrichr analysis. Edges are colored based on their pathway of origin. Nodes colored in red and green are shared between 2 and 3 pathways, respectively.
Figure 3

Multiple overlapping pathways identified using Enrichr analysis. Edges are colored based on their pathway of origin. Nodes colored in red and green are shared between 2 and 3 pathways, respectively.
Figure 4

RT-qPCR analysis of miR-451a, let-7f, miR-338 and miR-34a levels in 30 ALS and 30 control. (A) The fold change of expression value \(2^{-\Delta\Delta Ct}\) of miRNAs in ALS (gray) and control (white) normalized by the mean expression levels \(\Delta Ct\) of all controls. The boxplots are showing the median expression in ALS relative to control. (B) The CT of expression levels are presented as bar plots showing the error bars of miRNA expression in ALS and control.

Figure 5

The ROC curve of let-7f-5p and miR-338-3p in distinguishing ALS patients and healthy controls.
Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- SupplementaryInformation.pdf